The year 2026 stands as a watershed moment for global cybersecurity leadership. Threat actors have crossed a decisive ...

Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, ...

Duchenne: Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be generally well ...

Q2 2026 Earnings Call Transcript January 6, 2026 AAR Corp. beats earnings expectations. Reported EPS is $1.18, expectations ...

Precision BioSciences, Inc. , a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today ...

Brookdale Senior Living Inc. reported today its occupancy for December 2025.Fourth Quarter and December 2025 Occupancy ...

A practical overview of security architectures, threat models, and controls for protecting proprietary enterprise data in retrieval-augmented generation (RAG) systems.

Precigen transitioned to a commercial stage company with the US approval of PAPZIMEOS in August 2025, the first-and-only FDA-approved treatment for adults with RRP ...

Detailed price information for Mundoro Capital Inc (MUN-X) from The Globe and Mail including charting and trades.

The reverse stock split will become effective on January 9, 2026 (the "Effective Date"), and the Common Stock is expected to begin trading on the split-adjusted basis on the Nasdaq Stock Exchange ...

Scientists are testing CRISPR gene editing as a potential HIV cure after successfully removing the virus from infected cells ...

Pests are providing issues for farmers on both sides of Lake Taupō. Disease eradication agency Ospri has been working to ...